Sentence: A recently reported phase II trial has demonstrated that trastuzumab plus vinorelbine is both effective ( overall response rate 75 % ) and well tolerated , with the major side effects being typical of single-agent vinorelbine .
Drug combination annotation:
[{'class': 'POS', 'spans': ['trastuzumab', 'vinorelbine'], 'is_context_needed': False}]